Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale
- 15 February 2024
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (5) , 616-626
Abstract
Objective: Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcomes, including contractures, hemiatrophy, uveitis, and seizures. Despite improvements in treatment, >25% of patients with jLS have functional impairment. To improve patient evaluation, our workgroup developed the Localized scleroderma Total Severity Scale (LoTSS), an overall disease severity measure.Methods: LoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multicriteria decision analysis. Feasibility was assessed in larger Childhood Arthritis and Rheumatology Research Alliance groups. Construct validity with physician assessment and inter‐rater reliability was assessed using case vignettes. Additional evaluation was performed in a prospective patient cohort initiating treatment.Results: LoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by a strong positive correlation with the Physician Global Assessment (PGA) of severity and damage and weak positive correlation with PGA‐Activity, as expected. LoTSS was responsive, with a small effect size identified. Moderate‐to‐excellent inter‐rater reliability was demonstrated. LoTSS was able to discriminate between patient subsets, with higher scores identified in those with greater disease burden and functional limitation.Conclusion: We developed a new LS measure for assessing cutaneous and extracutaneous severity and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the major extracutaneous manifestations in LS. Our findings suggest LoTSS could aid assessment and management of patients and facilitate outcome evaluation in treatment studies. imageKeywords
Funding Information
- AF
- NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases
- NIH (RC2‐AR0‐58934)
- DCRI
This publication has 38 references indexed in Scilit:
- Localized scleroderma with pulmonary arterial hypertension and pulmonary interstitial fibrosis in a patient with positive Th/to antibodies: Case report and review of literatureClinical Case Reports, 2023
- Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy RegistryACR Open Rheumatology, 2019
- Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature reviewAutoimmunity Reviews, 2018
- Predictors of Longitudinal Quality of Life in Juvenile Localized SclerodermaArthritis Care & Research, 2016
- CNS imaging findings associated with Parry–Romberg syndrome and en coup de sabre: correlation to dermatologic and neurologic abnormalitiesNeuroradiology, 2014
- Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized sclerodermaArthritis Care & Research, 2012
- Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trialArthritis & Rheumatism, 2011
- Localized scleroderma in childhood is not just a skin diseaseArthritis & Rheumatism, 2005
- Measurement of health status in children with juvenile rheumatoid arthritisArthritis & Rheumatism, 1994
- The american college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritisArthritis & Rheumatism, 1992